ImmuCell Corp Q3 2025: Milk‑Derived Antibody Growth Fuels Investor Interest
ImmuCell Corp reports Q3 2025 results, showing growth from expanded production and new sales agreements for its milk‑derived passive antibody products, positioning it for livestock health market gains.
3 minutes to read